Geron Corporation

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

President-elect Donald Trump’s plan to nominate Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services was not entirely unexpected, but it sent biopharmaceutical stock va

Oncolytic viruses are, according to the Evaluate consensus, forecast to have the highest compound average growth rate (CAGR) of any technology over the next six years – with current estimates at 66%.

The US FDA convened five advisory committee meetings to discuss NMEs and novel biologics during the first half of the year. Two of the meetings took place after the user fee goal date had passed, sugg